Johnson & Johnson: Hypertension trials
The registry lists 12 Hypertension studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 1Phase 2 3Phase 3 4Phase 4 3No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical TrialCompletedNCT02382016Phase 4Results posted
- Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive AgentsCompletedNCT01939496Phase 4Results posted
- A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes MellitusCompletedNCT01483781Phase 1
- Pulmonary Artery Remodelling With BosentanCompletedNCT00595049Phase 4
- REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease ManagementCompletedNCT00370214
- A Study of Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential HypertensionCompletedNCT00236665Phase 3
- A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With ObesityCompletedNCT00236639Phase 3
- A Study of the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Patients With Type 2 DiabetesCompletedNCT00236626Phase 2
- A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With ObesityCompletedNCT00236613Phase 2
- A Study on Efficacy and Safety of Topiramate in Maintaining Weight Loss in Obese Patients Following an Intensive, Non-Pharmacologic Weight Loss ProgramCompletedNCT00236600Phase 3
- A Study of Safety and Efficacy of Topiramate in Male Patients With Abdominal ObesityCompletedNCT00231608Phase 2
- A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled DietCompletedNCT00231530Phase 3